Lundbeck teams with Otsuka on Alzheimer's vaccine development

Lundbeck and Otsuka have begun collaborating on development of a preclinical Alzheimer's disease vaccine candidate. The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year. Lundbeck is financing the trial and has received $5.5 million from Otsuka. Once Phase I data is in, the partners will decide whether to establish an alliance for the rest of development and commercialization. Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.